
Alzheimer's Disease Medications

Fact Sheet

Five prescription drugs currently are approved by the U.S. Food and Drug Administration to treat people who have been diagnosed with Alzheimer's disease (AD). Treating the symptoms of AD can provide patients with comfort, dignity, and independence for a longer period of time and can encourage and assist their caregivers as well. It is important to understand that none of these medications stops the disease itself



Treatment for Mild to Moderate AD

Four of these medications are called cholinesterase inhibitors. These drugs are prescribed for the treatment of mild to moderate AD. They may help delay or prevent symptoms from becoming worse for a limited time and may help control some behavioral symptoms. The medications are: Reminyl[®] (galantamine), Exelon[®] (rivastigmine), Aricept® (donepezil), and Cognex® (tacrine). Scientists do not yet fully understand how cholinesterase inhibitors work to treat AD, but current research indicates that they prevent the breakdown of acetylcholine, a brain chemical believed to be important for memory and thinking. As AD progresses, the brain produces less and less acetylcholine; therefore, cholinesterase inhibitors may eventually lose their effect.

No published study directly compares these drugs. Because all four work in a similar way, it is not expected that switching from one of these drugs to another will produce significantly different results. However, an AD patient may respond better to one

Fact Sheet

Fact Sheet

drug than another. Cognex[®] (tacrine) is no longer actively marketed by the manufacturer.

Treatment for Moderate to Severe AD

The fifth approved medication, known as Namenda® (memantine), is an N-methyl D-aspartate (NMDA) antagonist. It is prescribed for the treatment of moderate to severe AD. Studies have shown that the main effect of Namenda® is to delay progression of some of the symptoms of moderate to severe AD. The medication may allow patients to maintain certain daily functions a little longer. For example, Namenda® may help a patient in the later stages of AD maintain his or her ability to go to the bathroom independently for several more months, a benefit for both patients and caregivers.

Namenda® is believed to work by regulating glutamate, another important brain chemical that, when produced in excessive amounts, may lead to brain cell death. Because NMDA antagonists work very differently from cholinesterase inhibitors, the two

types of drugs can be prescribed in combination.

Dosage and Side Effects

Doctors usually start patients at low drug doses and gradually increase the dosage based on how well a patient tolerates the drug. There is some evidence that certain patients may benefit from higher doses of the cholinesterase inhibitor medications. However, the higher the dose, the more likely are side effects. The recommended effective dosage of Namenda® is 20 mg/day after the patient has successfully tolerated lower doses. Some additional differences among these medications are summarized in the table on the other side.

Patients may be drug-sensitive in other ways, and they should be monitored when a drug is started. Report any unusual symptoms to the prescribing doctor right away. It is important to follow the doctor's instructions when taking any medication, including vitamins and herbal supplements. Also, let the doctor know before adding or changing any medications.

Fact Sheet Fact Sheet

For More Information

To learn about support groups, services, research centers, and publications about AD, contact the following groups:

Alzheimer's Association

225 N. Michigan Avenue, Suite 1700 Chicago, IL 60601 1-800-272-3900

Website: www.alz.org

This non-profit association supports AD research and families and caregivers of patients with AD. Nationwide chapters provide referrals to local resources.

Alzheimer's Disease Education and Referral (ADEAR) Center

P.O. Box 8250 Silver Spring, MD 20907-8250 1-800-438-4380

Website: www.alzheimers.org

This service of the National Institute on Aging offers information and publications on diagnosis, treatment, patient care, caregiver needs, longterm care, and research related to AD.

NIH Publication No. 03-3431

July 2004

Note: The brief summary provided below does not include all information important for using these or any other medications or supplements. Drugs are listed in order, as appro

DRUG NAME	DRUG TYPE AND TREATMENT	
Namenda® (memantine) Blocks the toxic effects associated with excess glutamate and regulates glutamate activation.	N-methyl D-aspartate (NMDA) antagonist prescribed to treat symptoms of moderate to severe AD	•
Reminyl ® (galantamine) Prevents the breakdown of acetylcholine and stimulates nicotinic receptors to release more acetylcholine in the brain.	Cholinesterase inhibitor prescribed to treat symptoms of mild to moderate AD	•
Exelon ® (rivastigmine) Prevents the breakdown of acetylcholine and butyrylcholine (a brain chemical similar to acetylcholine) in the brain.	Cholinesterase inhibitor prescribed to treat symptoms of mild to moderate AD	•
Aricept [®] (donepezil) Prevents the breakdown of acetylcholine in the brain.	Cholinesterase inhibitor pre- scribed to treat symptoms of mild to moderate AD	•
Cognex® (tacrine) Prevents the breakdown of acetylcholine in the brain. Note: Cognex is still available but no longer actively marketed by the manufacturer.	Cholinesterase inhibitor prescribed to treat symptoms of mild to moderate AD	•

^{*} Use of cholinesterase inhibitors can increase risk of stomach ulcers, and because prolonged use of non-stero

ant for patient use and should not be used as a substitute for professional medical advice approved by the U.S. Food and Drug Administration, starting with the most recent. MANUFACTURER'S RECOMMENDED **COMMON SIDE DOSAGE EFFECTS** 5 mg, once a day Dizziness, headache, 0 Increase to 10 mg/day (5 mg twice a day), 15 mg/ constipation, ar day (5 mg and 10 mg as separate doses), and 20 confusion re mg/day (10 mg twice a day) at minimum of one as week intervals if well tolerated. sk 4mg, twice a day (8mg/day) Nausea, vomiting, So Increase by 8mg/day after 4 weeks to 8mg, twice a diarrhea, weight loss fl day (16mg/day)if well tolerated. ac After another 4 weeks, increase to 12mg, twice a in day (24mg/day) if well tolerated. CC 1.5mg, twice a day (3mg/day) Nausea, vomiting, N

on-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen can also cause stomach ulcers, N

weight loss, upset

Nausea, diarrhea,

Nausea, diarrhea,

possible liver

damage

stomach, muscle

weakness

vomiting

W

N

W

N

m

Increase by 3mg/day every 2 weeks to 6mg, twice

Increase after 4-6 weeks to 10mg, once a day if

Increase by 40mg/day every 4 weeks to 40mg,

four times a day (160mg/day), if liver enzyme

functions remain normal and if well tolerated.

a day (12mg/day) if well tolerated.

10mg, four times a day (40mg/day)

5mg, once a day

well tolerated.

Medications to Treat Alzheimer's Disease

advice. Consult the prescribing doctor and read the package insert before nt.

0	POSSIBLE DRUG INTERACTIONS
е,	Other NMDA antagonist medications, including amantadine, an antiviral used to treat the flu, dextromethorphan, prescribed to relieve coughs due to colds or flu, and ketamine, sometimes used as an anesthetic, have not been systematically evaluated and should be used with caution in combination with this medication.
SS	Some antidepressants such as paroxetine, amitriptyline, fluoxetine, fluoxamine, and other drugs with anticholinergic action may cause retention of excess Reminyl in the body, leading to complications; NSAIDs should be used with caution in combination with this medication.*
	None observed in laboratory studies; NSAIDs should be used with caution in combination with this medication.*
	None observed in laboratory studies; NSAIDs should be used with caution in combination with this medication.*
	NSAIDs should be used with caution in combination with this medication.*
cers	s, NSAIDs should be used with caution in combination with these medications.